New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.

Mesa RA

Choosing between stem cell therapy and drugs in myelofibrosis.

Kröger N, Mesa RA

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A, International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)

Extramedullary hematopoiesis.

Knoll B, Rea DJ, Szoztek J, Nagorney DS, Tefferi A, Mesa RA

Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis.

Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.

Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A

Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.

Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP, Gilliland DG, Tefferi A

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.

Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA

The dawn of targeted therapy for primary myelofibrosis: opportunities and challenges.

Mesa RA

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.

Mesa RA